Correlation Engine 2.0
Clear Search sequence regions


  • 3 utr (2)
  • adult (1)
  • allele (2)
  • asian (1)
  • child (1)
  • CYP3A4 (3)
  • CYP3A5 (7)
  • cyp3a5 protein, human (1)
  • drug dose (2)
  • factors (3)
  • female (1)
  • FKBP1A (1)
  • FKBP1A protein (1)
  • genes (1)
  • help (1)
  • humans (2)
  • mirn500 microrna, human (1)
  • mirna (3)
  • mirna (3)
  • myasthenia gravis (3)
  • NFATC (2)
  • NFATC2 (2)
  • P 450 (2)
  • patients (2)
  • protein human (3)
  • rs15524 (5)
  • SNPs (5)
  • tacrolimus (10)
  • young adult (1)
  • Sizes of these terms reflect their relevance to your search.

    Tacrolimus is a novel effective immunosuppressant for myasthenia gravis (MG) patients. However, the narrow therapeutic window, and high inter- and intrapatient variation in bioavailability largely limited its clinical application. This article intended to find the SNPs influencing clinical outcome and discover the possible mechanisms. Based on the tagSNPs genotyped by Improved Multiple Ligase Detection Reaction, Plink 1.07 was used to find the SNPs having close interaction to tacrolimus serum concentration, QMG score changes or even reasonable drug dose. Then we searched several databases to predict the possible miRNA binding rs15524 sequence. Based on the prediction, dual-luciferase reporter assay and miRNA transfection were used to discover the mechanism of how SNP rs15524 controls tacrolimus serum concentration through influencing CYP3A5 expression. In this article, we found multiple SNPs on CYP3A4, CYP3A5, FKBP1A, NFATC2 genes were predicted closely related to tacrolimus serum concentration, therapeutic effect which reflected by QMG score changes or even reasonable drug dose. After in silico miRNA selection, possible relationship between hsa-miR-500a and rs15524 was found. With the help of dual-luciferase reporter assay, wild-type rs15524 (T allele) was found having a stronger binding affinity for hsa-miR-500a. Higher expression of CYP3A5 may also led by lower hsa-miR-500a level. SNP rs15524 may control CYP3A5 expression by affecting the binding affinity between CYP3A5 3'UTR and hsa-miR-500a. Wild type (T allele) 3'UTR of CYP3A5 has stronger binding affinity to hsa-miR-500a and cause lower CYP3A5 expression and higher tacrolimus serum concentration.

    Citation

    Huan-Yu Meng, Xi Li, Wan-Lin Jin, Cheng-Kai Yan, Xiao-Hua Dong, Qiu Xu, Yu-Yao Peng, Zhi-Bin Li, Yi Li, Zhao-Hui Luo, Li-Qun Xu, Huan Yang. Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients. European journal of clinical pharmacology. 2020 May;76(5):659-671

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 31955224

    View Full Text